![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Rugo, H. S.; Dieras, V.; Gelmon, K. A.; Finn, R. S.; Slamon, D. J.; Martin, M.; Neven, P.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. Huang; Iyer, S.; Johnston, S.; Ettl, J. und Harbeck, N.
(2018):
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
In: Annals of Oncology, Bd. 29, Nr. 4: S. 888-894
Harbeck, N.; Iyer, S.; Turner, N.; Cristofanilli, M.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Bhattacharyya, H.; Theall, K. Puyana; Bartlett, C. H. und Loibl, S.
(2016):
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
In: Annals of Oncology, Bd. 27, Nr. 6: S. 1047-1054
Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A. und Harbeck, N.
(2016):
Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer.
In: Annals of Oncology, Bd. 27
Rugo, H.; Dieras, V.; Gelmon, K. A.; Finn, R.; Slamon, D.; Miguel, M.; Neven, P.; Ettl, J.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. H.; Iyer, S.; Johnston, S. und Harbeck, N.
(2016):
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naive postmenopausal patients with ER+HER2-metastatic breast cancer (MBC): results from PALOMA-2.
In: Annals of Oncology, Bd. 27